NASDAQ:HSIC - Henry Schein Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $80.52 -3.27 (-3.90 %) (As of 12/14/2018 04:00 PM ET)Previous Close$80.52Today's Range$80.48 - $83.6352-Week Range$62.56 - $91.35Volume1.63 million shsAverage Volume1.30 million shsMarket Capitalization$12.77 billionP/E Ratio22.37Dividend YieldN/ABeta0.89 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Henry Schein, Inc. provides health care products and services to dental practitioners and laboratories, animal health clinics, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment offers dental products, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, and high-tech and digital restoration equipment, as well as equipment repair services. This segment also provides animal health products, such as branded and generic pharmaceuticals, surgical and consumable products and services, and equipment; and medical products comprising branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray products, equipment, and vitamins. The Technology and Value-Added Services segment offers software, technology, and other value-added services that include practice management software systems for dental and medical practitioners, and animal health clinics. This segment also provides value-added practice solutions, which comprise financial services on a non-recourse basis, e-services, practice technology, network, and hardware services, as well as continuing education services for practitioners. The company was founded in 1932 and is headquartered in Melville, New York. Receive HSIC News and Ratings via Email Sign-up to receive the latest news and ratings for HSIC and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Medical & hospital equipment Sub-IndustryHealth Care Distributors SectorMedical Current SymbolNASDAQ:HSIC Previous Symbol CUSIP80640710 Webwww.henryschein.com Phone631-843-5500 Debt Debt-to-Equity Ratio0.29 Current Ratio1.30 Quick Ratio0.70 Price-To-Earnings Trailing P/E Ratio22.37 Forward P/E Ratio19.54 P/E Growth2.76 Sales & Book Value Annual Sales$12.46 billion Price / Sales0.98 Cash Flow$4.6732 per share Price / Cash Flow17.23 Book Value$18.00 per share Price / Book4.47 Profitability EPS (Most Recent Fiscal Year)$3.60 Net Income$406.29 million Net Margins3.00% Return on Equity20.40% Return on Assets7.71% Miscellaneous Employees22,000 Outstanding Shares152,440,000Market Cap$12.77 billion OptionableOptionable Henry Schein (NASDAQ:HSIC) Frequently Asked Questions What is Henry Schein's stock symbol? Henry Schein trades on the NASDAQ under the ticker symbol "HSIC." When did Henry Schein's stock split? How did Henry Schein's stock split work? Henry Schein shares split before market open on Friday, September 15th 2017. The 2-1 split was announced on Wednesday, August 16th 2017. The newly issued shares were issued to shareholders after the closing bell on Thursday, September 14th 2017. An investor that had 100 shares of Henry Schein stock prior to the split would have 200 shares after the split. How will Henry Schein's stock buyback program work? Henry Schein declared that its board has approved a share buyback program on Thursday, December 13th 2018, which allows the company to buyback $400,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to repurchase up to 3.1% of its stock through open market purchases. Stock buyback programs are usually an indication that the company's management believes its stock is undervalued. How were Henry Schein's earnings last quarter? Henry Schein, Inc. (NASDAQ:HSIC) released its earnings results on Tuesday, November, 6th. The company reported $1.03 EPS for the quarter, beating the consensus estimate of $1.01 by $0.02. The business earned $3.28 billion during the quarter, compared to analysts' expectations of $3.37 billion. Henry Schein had a net margin of 3.00% and a return on equity of 20.40%. The business's quarterly revenue was up 3.8% on a year-over-year basis. During the same quarter last year, the company earned $0.87 EPS. View Henry Schein's Earnings History. When is Henry Schein's next earnings date? Henry Schein is scheduled to release their next quarterly earnings announcement on Tuesday, February 19th 2019. View Earnings Estimates for Henry Schein. What guidance has Henry Schein issued on next quarter's earnings? Henry Schein updated its FY18 earnings guidance on Tuesday, November, 6th. The company provided EPS guidance of $4.06-4.14 for the period, compared to the Thomson Reuters consensus estimate of $4.12. What price target have analysts set for HSIC? 16 Wall Street analysts have issued 12 month price objectives for Henry Schein's stock. Their forecasts range from $66.00 to $102.00. On average, they anticipate Henry Schein's stock price to reach $85.6429 in the next year. This suggests a possible upside of 6.4% from the stock's current price. View Analyst Price Targets for Henry Schein. What is the consensus analysts' recommendation for Henry Schein? 16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Henry Schein in the last year. There are currently 2 sell ratings, 6 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Henry Schein. What are Wall Street analysts saying about Henry Schein stock? Here are some recent quotes from research analysts about Henry Schein stock: 1. Barrington Research analysts commented, "We are currently modeling $4.10. It is important to note that management’s adjusted EPS guidance does not include any impact from the upcoming animal health spin-off and merger, which is expected to occur around year end. In addition, the guidance does not factor in any future M&A activity." (11/8/2018) 2. According to Zacks Investment Research, "In the past six months, Henry Schein has outperformed its industry. The company's operating segments recorded strong year-over-year growth in the last reported quarter. Strong share gain in the North America and overseas along with solid revenues is encouraging. Despite the better-than-expected revenue performance, we are disappointed with the year-over-year deterioration in gross and operating margin due to higher cost and expenses. We currently await the completion planned spin-off of the company’s global Animal Health business. This business contributes nearly 30% to the top line. The spin-off is expected to bring in major changes to Henry Schein’s overall operating results. On the flip side, pricing pressure and tough competition are major woes." (10/5/2018) Has Henry Schein been receiving favorable news coverage? Media coverage about HSIC stock has been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Henry Schein earned a news impact score of 1.2 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the stock's share price in the immediate future. Who are some of Henry Schein's key competitors? Some companies that are related to Henry Schein include Allergan (AGN), Illumina (ILMN), Celgene (CELG), HCA Healthcare (HCA), Vertex Pharmaceuticals (VRTX), Zoetis (ZTS), Humana (HUM), Regeneron Pharmaceuticals (REGN), Baxter International (BAX), Edwards Lifesciences (EW), Actelion (ALIOF), ASTELLAS PHARMA/ADR (ALPMY), ESSILOR Intl S/S (ESLOY), Centene (CNC) and Takeda Pharmaceutical (TKPYY). Who are Henry Schein's key executives? Henry Schein's management team includes the folowing people: Mr. Stanley M. Bergman, Exec. Chairman & CEO (Age 68)Mr. James P. Breslawski, Vice Chairman & Pres (Age 64)Mr. Steven Paladino, Exec. VP, CFO & Exec. Director (Age 61)Mr. Gerald A. Benjamin, Exec. VP, Chief Admin. Officer & Director (Age 65)Mr. Robert Minowitz, Sr. VP of Global Dental Merchandising & Bus. Operations (Age 59) Who are Henry Schein's major shareholders? Henry Schein's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Vanguard Group Inc (10.67%), Longview Partners Guernsey LTD (8.92%), BlackRock Inc. (6.94%), FMR LLC (5.69%), Select Equity Group L.P. (4.08%) and Brown Brothers Harriman & Co. (3.40%). Company insiders that own Henry Schein stock include Barry J Alperin, David Mckinley, Donald J Kabat, Gerald A Benjamin, James A Harding, Lorelei Mcglynn, Mark E Mlotek, Michael Racioppi, Michael S Ettinger, Paul Brons, Paul Rose, Philip A Laskawy, Stanley M Bergman and Steven Paladino. View Institutional Ownership Trends for Henry Schein. Which major investors are selling Henry Schein stock? HSIC stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Mackenzie Financial Corp, Deutsche Bank AG, Alecta Pensionsforsakring Omsesidigt, Select Equity Group L.P., Brown Brothers Harriman & Co., Schroder Investment Management Group and JPMorgan Chase & Co.. Company insiders that have sold Henry Schein company stock in the last year include David Mckinley, Mark E Mlotek, Michael S Ettinger, Paul Brons, Stanley M Bergman and Steven Paladino. View Insider Buying and Selling for Henry Schein. Which major investors are buying Henry Schein stock? HSIC stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Atlanta Capital Management Co. L L C, Morgan Stanley, AXA, American Century Companies Inc., WINTON GROUP Ltd, Ancora Advisors LLC and First Trust Advisors LP. View Insider Buying and Selling for Henry Schein. How do I buy shares of Henry Schein? Shares of HSIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Henry Schein's stock price today? One share of HSIC stock can currently be purchased for approximately $80.52. How big of a company is Henry Schein? Henry Schein has a market capitalization of $12.77 billion and generates $12.46 billion in revenue each year. The company earns $406.29 million in net income (profit) each year or $3.60 on an earnings per share basis. Henry Schein employs 22,000 workers across the globe. What is Henry Schein's official website? The official website for Henry Schein is http://www.henryschein.com. How can I contact Henry Schein? Henry Schein's mailing address is 135 DURYEA RD, MELVILLE NY, 11747. The company can be reached via phone at 631-843-5500 or via email at [email protected] MarketBeat Community Rating for Henry Schein (NASDAQ HSIC)Community Ranking: 1.8 out of 5 ()Outperform Votes: 255 (Vote Outperform)Underperform Votes: 448 (Vote Underperform)Total Votes: 703MarketBeat's community ratings are surveys of what our community members think about Henry Schein and other stocks. Vote "Outperform" if you believe HSIC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HSIC will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/15/2018 by MarketBeat.com StaffFeatured Article: How does a reverse stock split work?